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Background
Recombinant therapeutic proteins are increasingly
requested with advances in tissue engineering using
stem cells. Human cell line is an attractive host for the
production of such glycoprotein, but there are few
reports on human cells for a commercial production [1].
In this study, we established new human lymphoid cell
lines from peripheral blood mononuclear cells (PBMCs)
by treatment with phorbol 12-myristate 13-acetate
(PMA) under a non-GMP condition, and characterized
them by gene and protein expression analyses.
Experimental Approach
The human PBMCs (2 × 106 cells/ml) were cultured in 24
well plates in 12.5%FBS-ERDF medium supplemented with
10 ng/ml of IL-4 and/or IL-6 and 1 µg/ml of PMA for three
months. The medium was changed every two or three days.
The gene expression of telomerase reverse transcrip-
tase (TERT), a marker of immortalization, was examined
by RT-PCR. The immunoglobulin (Ig) isotype was con-
firmed by ELISA. The CD markers on cell surface were
detected by flow cytometry.
Results and Discussion
Although normal human cells are difficult to be trans-
formed by chemical reagents such as PMA, we succeeded
in obtaining three human cell clones under above condi-
tion (Table 1). The key point in our transformation may
be continuous stationary culture without passage. All
obtained clones were able to be subcultured over one
year and were found to express TERT. In addition, they
produced any isotype of immunoglobulin in the medium,
indicating B lymphocytes. The results of flow cytometry
also supported it. Therefore, these clones may be suitable
for the production of secreted human glycoprotein
because mature B lymphocytes have the extensive endo-
plasmic reticulum. In the next step, we will establish
GMP compliant new human lymphoid cell lines.
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Table 1. Summary of cell establishment and characterization
Clone1 Clone2 Clone3
Culture medium for transformation 12.5%FBS-ERDF +IL-4+IL-6+PMA 12.5%FBS-ERDF +IL-6+PMA 12.5%FBS-ERDF +IL-4+IL-6+PMA






Possible period of subculture Over 1 year Over 1 year Over 2 years
Mean doubling time 30 hours 30 hours 30 hours
TERT expression Positive Positive Positive
Produced Immunoglobulin IgG IgM IgG
B cell marker (CD19) Positive Positive Positive
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